COM:BIORATHERAPEUTICS
Biora Therapeutics, Inc.
- Stock
Last Close
1.63
22/11 21:00
Market Cap
23.40M
Beta: -
Volume Today
82.22K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
average inventory | 9.28M - | 11.58M 24.81% | 7.18M 37.96% | 2.38M 66.94% | 1.30M 45.20% | ||
average payables | 13.39M - | 16.58M 23.80% | 13.06M 21.24% | 6.16M 52.85% | 3.22M 47.63% | ||
average receivables | 15.48M - | 17.75M 14.65% | 6.67M 62.44% | 740.50K 88.89% | 829K 11.95% | ||
book value per share | -34.28 - | -59.80 74.46% | -97.22 62.57% | -22.09 77.28% | -13.40 39.36% | -6.43 52.00% | |
capex per share | -4.48 - | -2.66 40.72% | -4.49 69.15% | -0.22 95.05% | -0.10 53.34% | -0.01 93.70% | |
capex to depreciation | -0.80 - | -0.59 26.26% | -0.98 66.57% | -0.59 39.12% | -0.87 46.76% | -0.19 78.75% | |
capex to operating cash flow | 0.07 - | 0.04 52.69% | 0.03 15.02% | 0.01 82.89% | 0.01 140.84% | 0.00 82.73% | |
capex to revenue | -0.04 - | -0.03 31.48% | -0.07 157.16% | -0.69 930.59% | -2.60 278.73% | -25.75 891.64% | |
cash per share | 64.17 - | 23.56 63.29% | 83.67 255.14% | 22.98 72.53% | 3.99 82.63% | 0.96 75.85% | |
days of inventory on hand | 30.19 - | 39.72 31.58% | 47.73 20.16% | ||||
days payables outstanding | 43.74 - | 57.22 30.81% | 68.01 18.86% | ||||
days sales outstanding | 23.23 - | 57.86 149.02% | 62.29 7.66% | 191.13 206.85% | 990.89 418.42% | 75.74K 7,543.42% | |
debt to assets | 0.62 - | 0.72 15.42% | 1.05 45.71% | 1.16 10.51% | 2.40 107.04% | 1.46 39.10% | |
debt to equity | -1.97 - | -0.87 55.54% | -1.52 73.41% | -1.49 1.94% | -1.26 15.41% | -0.45 64.18% | |
dividend yield | 0.01 - | ||||||
earnings yield | -0.36 - | -0.32 11.83% | -1.32 309.52% | -0.89 32.59% | -1.94 118.16% | -5.83 200.75% | |
enterprise value | 377.47M - | 500.36M 32.56% | 216.33M 56.77% | 238.97M 10.47% | 122.52M 48.73% | 51.79M 57.73% | |
enterprise value over ebitda | -3.47 - | -3.76 8.17% | -1.11 70.50% | -3.75 238.60% | -2.07 44.82% | -0.77 62.63% | |
ev to operating cash flow | -5.80 - | -4.71 18.65% | -1.31 72.32% | -1.43 9.32% | -1.90 33.30% | -1.07 43.85% | |
ev to sales | 2.95 - | 3.48 17.82% | 2.91 16.23% | 191.64 6,483.10% | 401.71 109.62% | 12.95K 3,123.42% | |
free cash flow per share | -64.87 - | -78.32 20.74% | -155.10 98.03% | -43.77 71.78% | -8.54 80.49% | -3.08 63.92% | |
free cash flow yield | -0.20 - | -0.24 20.74% | -1.17 389.28% | -0.84 28.30% | -2.59 208.96% | -2.28 11.81% | |
graham net net | -68.84 - | -92.67 34.62% | -139.70 50.74% | -27.00 80.67% | -16.16 40.14% | -7.41 54.18% | |
graham number | 303.86 - | 376.86 24.02% | 618.62 64.15% | 151.90 75.45% | 43.91 71.09% | 33.74 23.16% | |
income quality | 0.50 - | 0.72 42.11% | 0.86 20.09% | 0.94 8.98% | 1.69 79.94% | 0.39 76.85% | |
intangibles to total assets | 0.10 - | 0.11 5.51% | 0.07 39.69% | 0.06 14.37% | 0.11 103.34% | 0.19 71.47% | |
interest coverage | -12.57 - | -15.23 21.21% | -5.60 63.25% | 9.33 266.61% | -5.62 160.28% | -6.84 21.69% | |
interest debt per share | 75.88 - | 58.87 22.41% | 179.17 204.33% | 29.58 83.49% | 18.30 38.15% | 3.52 80.76% | |
inventory turnover | 12.09 - | 9.19 24.00% | 7.65 16.78% | ||||
invested capital | -1.97 - | -0.87 55.54% | -1.52 73.41% | -1.49 1.94% | -1.26 15.41% | -0.45 64.18% | |
market cap | 353.73M - | 460.03M 30.05% | 146.09M 68.24% | 200.96M 37.56% | 25.20M 87.46% | 21.29M 15.49% | |
net current asset value | -64.42M - | -110.95M 72.24% | -135.10M 21.76% | -95.39M 29.39% | -117.70M 23.39% | -113.56M 3.51% | |
net debt to ebitda | -0.22 - | -0.30 38.68% | -0.36 18.83% | -0.60 65.87% | -1.65 175.62% | -0.46 72.29% | |
net income per share | -119.71 - | -105.55 11.83% | -174.94 65.74% | -46.42 73.47% | -6.40 86.22% | -7.87 23.04% | |
operating cash flow per share | -60.39 - | -75.67 25.30% | -150.61 99.04% | -43.55 71.09% | -8.44 80.63% | -3.07 63.56% | |
payables turnover | 8.34 - | 6.38 23.55% | 5.37 15.87% | ||||
receivables turnover | 15.71 - | 6.31 59.84% | 5.86 7.12% | 1.91 67.41% | 0.37 80.71% | 0.00 98.69% | |
research and ddevelopement to revenue | 0.38 - | 0.44 15.68% | 0.64 45.91% | 36.72 5,614.94% | 78.85 114.75% | 7.46K 9,360.47% | |
return on tangible assets | -1.24 - | -1.63 32.03% | -1.33 18.27% | -1.74 30.27% | -1.03 40.76% | -4.94 379.72% | |
revenue per share | 118.66 - | 102.66 13.49% | 67.53 34.22% | 0.32 99.52% | 0.04 87.68% | 0.00 99.37% | |
roe | 3.49 - | 1.76 49.46% | 1.80 1.95% | 2.10 16.75% | 0.48 77.28% | 1.22 156.35% | |
roic | -3.16 - | 14.81 568.38% | -2.93 119.81% | -2.84 3.15% | -2.32 18.40% | 1.20 151.94% | |
sales general and administrative to revenue | 0.40 - | 0.43 6.38% | 1.02 138.35% | 54.96 5,314.50% | |||
shareholders equity per share | -34.28 - | -59.80 74.46% | -97.22 62.57% | -22.09 77.28% | -13.40 39.36% | -6.43 52.00% | |
stock based compensation to revenue | 0.02 - | 0.02 6.72% | 0.14 770.31% | 9.59 6,582.19% | 25.59 166.74% | 4.12K 15,997.11% | |
tangible asset value | -48.89M - | -94.86M 94.05% | -117.06M 23.39% | -91.05M 22.22% | -108.36M 19.01% | -107.49M 0.80% | |
tangible book value per share | -45.33 - | -67.64 49.21% | -106.36 57.26% | -23.67 77.74% | -14.19 40.05% | -6.81 51.98% | |
working capital | 10.89M - | -25.69M 335.92% | 53.67M 308.91% | 36.82M 31.39% | 14.81M 59.77% | -43.90M 396.41% |
All numbers in USD (except ratios and percentages)